Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Finnish municipality has chosen Aino
Yet another Finnish municipality, Siilinjärvi, has chosen Aino's SaaS platform to be more socially sustainable and to achieve the operational goals with the existing staff. The agreement includes a total of 850 employees and the SaaS platform is in production use since the third quarter of 2024. “As a public organization we are working hard every day to find and to keep employees with the right competence. With Aino we will gain a more systematic and responsive leadership, boost employee...
Nasdaq GlobeNewswire
17/10/2024
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI®…
"Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our areas of focus," said Emmanuelle Lecomte Brisset, Senior Vice President and Head of Global Regulatory Affairs at CSL. "There is a high unmet medical need for a targeted therapy to treat IgAN and we look forward to providing access to this innovative treatment option for the Swiss IgAN community as fast as possible. Thank you to all of the patients…
PR Newswire
17/10/2024
Bio X Cell Announces Board of Director Appointments
"We are thrilled to welcome Alan Hirzel to the board alongside Kevin Ballinger, who joined earlier this year," said Chris Conway, CEO of Bio X Cell. "Alan and Kevin bring a wealth of experience and industry knowledge to the table, which will serve us well as we execute on BXC's extraordinary strategic growth opportunities following the Company's recent acquisition by Windjammer Capital Investors." "We are thrilled to welcome Alan Hirzel to the board alongsideKevin…
PR Newswire
17/10/2024
Press Release: Sanofi and Orano join forces to develop next-generation…
Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024.Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will...
Nasdaq GlobeNewswire
17/10/2024
Press Release: Sanofi and Orano join forces to develop next-generation…
Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024.Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will...
Nasdaq GlobeNewswire
17/10/2024
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
Press ReleaseNicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025October 17, 2024 – release at 7:30 am CETSophia...
Nasdaq GlobeNewswire
17/10/2024
Hansa Biopharma Reports Third Quarter and Interim January - September 2024…
Søren Tulstrup, President and CEO, Hansa Biopharma said, "The third quarter of 2024 marks the highest ever IDEFIRIX® sales performance to date, resulting in four consecutive quarters of strong sales performance. The launch of IDEFIRIX in Europe continues to advance with adoption in international organ allocation systems and an increase in new and repeat utilization in leading transplant clinics. Equally, we see strong momentum in our clinical development programs in autoimmune, gene therapy…
PR Newswire
17/10/2024
Eisai will request reconsideration of initial decision for lecanemab in…
Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, Israel UAE and Great Britain, and is being marketed in the United States, Japan and China. Lecanemab is already approved inthe United States,Japan,China,South Korea,Hong Kong, Israel UAE andGreat Britain, and is being marketed inthe United States,JapanandChina. Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was...
PR Newswire
17/10/2024
PARP Inhibitors Market to Register Immense Growth by 2034 Owing to Wider…
Key Takeaways from the PARP Inhibitors Market Report Key Takeaways from the PARP Inhibitors Market Report Discover which therapies are expected to grab the PARP inhibitors market share @ PARP Inhibitors Market Report PARP Inhibitors Market Dynamics The PARP inhibitors market has seen significant growth and transformation in recent years, driven primarily byadvancements in oncologyand theincreasing recognition of these drugs' therapeutic potential. One of the key dynamics...
PR Newswire
16/10/2024
Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New…
Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference on Wednesday, October 30th at 2:00pm ET (also viewable online at the conference portal). The Company's executive team will be available for one-on-one meetings at the event. Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference onWednesday, October 30th at2:00pm ET (also viewable online at the conference portal). The Company's executive team will be available for one-on-one...
PR Newswire
16/10/2024
Presagen's AI fertility product Life Whisperer acquired by Astec
The acquisition by Astec, with their strong global distribution network in the fertility sector, will accelerate the proliferation of this promising AI technology into IVF labs around the world. Astec also intends to make Life Whisperer a key feature of its embryo incubator product range. The acquisition by Astec, with their strong global distribution network in the fertility sector, will accelerate the proliferation of this promising AI technology into IVF labs around the world. Astec also...
PR Newswire
16/10/2024
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent…
Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, andLimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for...
Nasdaq GlobeNewswire
16/10/2024
Radiation Oncology Market Size Worth $23.62 Billion, Globally, by 2031 -…
Overview of Report Findings Overview of Report Findings 1. Market Growth: The radiation oncology market is expected to reachUS$ 23.62 billionby 2031 fromUS$ 8.92 billionin 2023; it is anticipated to register a CAGR of 13.0% from 2023 to 2031. Radiation oncology is the specialized medical treatment of cancer using radiation therapy. Radiation oncology is high-energy radiation therapy with X-rays or high energy particles to kill cancer cells or shrink tumors. Radiation oncologists...
PR Newswire
16/10/2024
Mars announces new leadership for its Veterinary Health and Science &…
President of Mars Petcare, Loïc Moutault said: "I'm delighted that Nef will step up to lead our Veterinary Health business, working with 70,000 passionate, pet-loving Associates. She is a hugely talented leader with decades of complementary experience across health and services. I'm confident under Nef's leadership we will harness the knowledge, talent, and resources across our organization to support the veterinary profession and deliver world leading care for pets." President of…
PR Newswire
16/10/2024
Acquisition of Ovizio Imaging Systems SA
ANNOUNCEMENT NO. 280 16 October 2024Acquisition of Ovizio Imaging Systems SAOn the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA ('Ovizio').The acquisition price is EUR 2,830,000.The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the...
Nasdaq GlobeNewswire
16/10/2024
Upgrade of revenue and operating profit guidance
ANNOUNCEMENT NO. 279 16 October 2024Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake.Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously. ChemoMetec's...
Nasdaq GlobeNewswire
16/10/2024
Digital Dentures Market to Hit USD 2.16 Billion by 2029 with 8.7% CAGR |…
Browse in-depth TOC on "Digital Dentures Market" Browse in-depth TOC on "Digital Dentures Market" 318 - Tables58 - Figures274 - Pages The convenience of digital workflows, which streamline the entire process from impression taking to final denture fitting, and the increasing investments by key market players in research and development to introduce innovative products which is driving the market's growth. Based on type, the digital denture market is segmented into...
PR Newswire
16/10/2024
mRNA Synthesis & Manufacturing Market to Hit USD 738.3 Million by 2029 with 3.4%…
Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market"250 - Tables50 - Figures250 - Pages Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market" 250 - Tables 50 - Figures 250 - Pages The market is expanding rapidly due to factors such as the development of mRNA-based vaccines and expanded applications such as cancer immunotherapies. Furthermore, improvements in mRNA synthesis technology, a rise in mRNA synthesis and modification outsourcing, and…
PR Newswire
16/10/2024
Renovaro Announces Strategic Restructuring and Leadership Transition
Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company's Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies Newly Appointed Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment...
Nasdaq GlobeNewswire
16/10/2024
Tanner Health and Healthliant Ventures Partner With Corti to Accelerate Medical…
Revolutionizing the Burden of Medical Coding Revolutionizing the Burden of Medical Coding "Healthcare systems are severely overburdened, with professionals spending almost 34 percent of their time on documentation," saidAndreas Cleve, CEO of Corti. "Our mission is to change this. Backed by over eight years of rigorous research, our peer-reviewed AI offers multiple models specifically built for healthcare so that it can be trusted to serve the industry's ultra complex and…
PR Newswire
16/10/2024
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the…
“We are very pleased with the European Commission's grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We have previouslyreportedencouraging results from an investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma, and we are working closely...
Nasdaq GlobeNewswire
16/10/2024
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with…
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 demonstrated statistically significant pain relief in a recently completed Phase 2 trial of dry eye diseaseLONDON and NEW YORK, Oct.16, 2024(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
16/10/2024
Telix Featured in 13 Abstracts at the Annual Congress of the European…
Dr. David N. Cade, Telix Group Chief Medical Officer, said, "We are pleased to be able to so comprehensively showcase our pipeline at EANM – the largest gathering of nuclear medicine professionals worldwide – with a sponsored symposium, and abstracts accepted across Telix's late-stage theranostic programs in kidney and brain cancers, and in bone marrow conditioning. As in previous years, it is an honour for us to support the EANM Sanjiv Sam Gambhir Young Investigator Award. This is an…
PR Newswire
16/10/2024
Trading by management and close relations of management
Please see the attached PDF for details. Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the vesting of...
Nasdaq GlobeNewswire
16/10/2024
Altri Comunicati
